Whether Arcturus Therapeutics (ARCT) represents a suitable purchase depends on your investment strategy, risk tolerance, and acceptance of biotechnology sector volatility. Biotech companies rely heavily on successful clinical research pipelines, regulatory milestones, and commercialization execution, making their valuations susceptible to sharp fluctuations. Are you seeking aggressive growth or stable income, and what percentage of your portfolio are you allocating to biotech? Performing rigorous due diligence on their drug pipeline and financial runway is critical prior to investing.